Aktis Oncology, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aktis Oncology, Inc. - overview
Established
2021
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Aktis Oncology, Inc. is a biotechnology company specializing in the development of precision radiopharmaceuticals focused on delivering targeted cancer therapies, primarily addressing significant unmet medical needs in oncology. Aktis Oncology, Inc. , founded in 2021, is based in Boston, US.
The company specializes in precision radiopharmaceuticals designed to target cancer cells specifically. The firm has engaged in three funding deals, with the most recent being a Series B round of USD 175. 00 mn on September 20, 2024, co-led by Janus Henderson Investors, RA Capital Management, and RTW Investments, among others. The total amount raised by the company currently stands at USD 175.
00 mn, which also reflects its latest funding round. The CEO of the company is Matthew Roden. Aktis Oncology specializes in the development of precision radiopharmaceuticals that leverage advanced platform technologies to deliver targeted therapies. Key offerings include alpha-emitting particles aimed at precisely targeting cancer cells, enhancing treatment options for patients with prevalent cancers.
The company's innovative approach addresses unmet medical needs, particularly in tumors with limited treatment alternatives, and is intended for use by oncologists and healthcare providers across North America and Europe. Aktis Oncology generates revenue through collaborations with healthcare institutions and oncology clinics that utilize its precision radiopharmaceuticals. The company engages in direct sales agreements with hospitals and cancer treatment centers, which include ongoing support and training for medical staff. Pricing strategies are in line with market standards for advanced cancer therapies, reflecting the precision and effectiveness of their flagship products.
In September 2024, Aktis Oncology, Inc. raised USD 175. 00 mn in Series B funding to support the research and development of its radiopharmaceuticals. The company plans to design and launch new products to enhance its therapeutic offerings, targeting an expansion into additional markets in North America and Europe.
The recent funding will facilitate these initiatives, enabling Aktis Oncology to broaden its footprint within the oncology sector and improve treatment options for cancer patients.
Current Investors
MPM BioImpact, Bristol-Myers Squibb Company, EcoR1 Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.aktisoncology.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aktis Oncology, Inc. - timeline of key events
Aktis Oncology, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.